PharmaVOICE
116 FOLLOWERS
PharmaVOICE is a resource for life-sciences executives and other healthcare-service related professionals. The primary research are made of by executive and corporate management from pharmaceutical, biotechnology, drug delivery, marketing communications, clinical services, contract research, drug development, and information technology companies, as well as other industry sectors.
PharmaVOICE
1d ago
The recent SCOTUS case involving mifepristone exposes the risk of drug safety determinations by judicial fiat ..read more
PharmaVOICE
1d ago
The FDA announced a June advisory committee date, potentially introducing a new Alzheimer’s treatment to compete with Eisai and Biogen’s Leqembi ..read more
PharmaVOICE
2d ago
The director of the University of Pittsburgh’s McGowan Institute for Regenerative Medicine believes the industry is “turning a corner ..read more
PharmaVOICE
4d ago
Tests frequently used in clinical trials will soon be regulated like medical devices — with some exceptions ..read more
PharmaVOICE
4d ago
With many chemo and ADHD drugs stuck in stubborn shortages, several agencies are looking for new solutions to boost supplies ..read more
PharmaVOICE
1w ago
With its next earnings report looming, pushback from an investor is adding pressure on Novavax to boost performance ..read more
PharmaVOICE
1w ago
Pricey gene therapies promise great benefit to patients but pose a threat to the payer landscape — ICER and a Tufts think tank are offering potential solutions ..read more
PharmaVOICE
1w ago
The FDA’s newly launched Center for Clinical Trial Innovation potentially opens the door for more efficient and expanded AI use, but leaves pharmas wanting more guidance ..read more
PharmaVOICE
1w ago
From resurrecting an extinct species to improving regenerative medicines with plant-based materials, these biotechs are on the leading edge of science ..read more
PharmaVOICE
1w ago
From its landmark CRISPR approval to its potential breakthrough drug for pain, Vertex’s development approach, led by chief scientific officer Dr. David Altshuler, is paying off ..read more